[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367369-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367369-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","escrt-may-function-as-a-tumor-biomarker-transitioning-from-pan-cancer-analysis-to-validation-within-breast-cancer","ESCRT may function as a tumor biomarker - transitioning from pan-cancer analysis to validation within breast cancer","","ESCRT is investigated as a tumor biomarker by integrating pan-cancer expression, prognostic significance, and immune microenvironment relevance, with further functional verification in breast cancer. Public multi-omics datasets and bioinformatics workflows evaluate differential expression, survival associations, and links to immune cell infiltration and stromal/immune scoring. Enrichment analyses indicate ESCRT-related immune functions and transport signaling pathways, supporting ESCRT as an early diagnostic marker and prognosis-associated factor. VPS37D is highlighted for breast cancer initiation, progression, and immune response.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/escrt-may-function-as-a-tumor-biomarker-transitioning-from-pan-cancer-analysis-to-validation-within-breast-cancer/367369/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/escrt-may-function-as-a-tumor-biomarker-transitioning-from-pan-cancer-analysis-to-validation-within-breast-cancer/367369.png","ImageObject",300,407,{"name":42,"@type":43},"\tJames","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-21","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What datasets and analytical tools were used to study ESCRT’s biomarker potential?","Question",{"text":63,"@type":64},"The study used TCGA, GTEX, HPA, GEO, CPTAC, R software, and bioinformatics methods to mine expression, prognostic value, and immune relevance across tumor types.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What key findings support ESCRT as a tumor biomarker across cancers?",{"text":68,"@type":64},"ESCRT showed significant differential expression and abnormal expression was associated with poor prognosis in multiple cancers, alongside associations with immune infiltration and stromal/immune score modulation.",{"name":70,"@type":61,"acceptedAnswer":71},"How is ESCRT further validated specifically for breast cancer?",{"text":72,"@type":64},"The workflow includes additional verification in breast cancer to confirm ESCRT family gene function and to highlight VPS37D’s role in tumor initiation, progression, and immune response.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367369,1791430309,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Original Research PUBLISHED 31 March 2025  \nDOI 10.3389/fimmu.2025.1531940  \nOPEN ACCESS  \nEDITED BY  \nKefah Mokbel,  \nPrincess Grace Hospital, United Kingdom  \nREVIEWED BY  \nDmitry Aleksandrovich Zinovkin, Gomel State Medical University, Belarus Shuai Xu,  \nVanderbilt University, United States Lili Liu,  \nVanderbilt University Medical Center, United States  \n*CORRESPONDENCE  \nJiang-shui Yuan  \n[yjs19790104@163.com](yjs19790104@163.com)[ ](yjs19790104@163.com)Wei-qing Song  \n [songweiqing68@163.com](songweiqing68@163.com)  \n†These author have contributed equally to this work  \nRECEIVED 21 November 2024  \nACCEPTED 07 March 2025  \nPUBLISHED 31 March 2025  \nCITATION  \nChen X-r, Tan X-y, Zhang Z-l, Yuan J-sand Song W-q (2025) ESCRT may function  \nas a tumor biomarker, transitioning from pan-cancer analysis to validation within breast cancer.  \nFront. Immunol. 16:1531940 .  \ndoi: 10.3389/fimmu.2025.1531940  \nCOPYRIGHT  \n© 2025 Chen, Tan, Zhang, Yuan and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nESCRT may function as a tumor biomarker, transitioning  \nfrom pan-cancer analysis to validation within breast cancer  \nXiao-rui Chen 1,2†, Xue-ying Tan 2†, Zong-liang Zhang 3, Jiang-shui Yuan 2* and Wei-qing Song 1,2*  \n1Qingdao Medical College, Qingdao University, Qingdao, China, 2Clinical Laboratory Department, Qingdao Municipal Hospital, Qingdao, China, 3 Department of Urology, Afﬁliated Hospital of Qingdao University, Qingdao, China  \nBackground: Studies have shown that ESCRT genes affect cell aging, immune environment, and tumors. BRCA was used to explore its effects on tumor prognosis and therapy.  \nMethods: The data sets of Cancer Genome Atlas (TCGA), Genome-Tissue Expression Plan (GTEX), Human Protein Mapping (HPA), Gene Expression Omnibus (GEO), Clinical Proteomic Tumor Analysis Consortium (CPTAC), R software package, and bioinformatics methods were used to mine the potential carcinogenic effects of ESCRT, including the expression level, prognostic value, and immune value of ESCRT in various types of tumor tissues, and the potential function of ESCRT family genes was further veriﬁed in breast cancer.  \nResults: ESCRT showed signiﬁcant differential expression in various cancers, such as bladder urothelial carcinoma and liver, cervical, renal, esophageal, head, and neck cancers (P \u003C0 . 05) . Abnormal ESCRT expression is associated with poor prognosis in various cancers, such as adrenocortical carcinoma, bladder urothelial carcinoma, breast cancer, and cervical cancer (P \u003C0 . 05) . The expression level of ESCRT was signiﬁcantly associated with immune cell inﬁltration and the modulation of the stromal/immune score (all P \u003C0 . 05) . Enrichment analysis showed that ESCRT is associated with immune-related functions and transport signaling pathways in various tumor cells. Moreover, ESCRT serves as an early diagnostic marker for several tumors and is signiﬁcantly associated with prognosis. This conﬁrms that ESCRT is associated with most immune-inﬁltrating cells in pan-carcinomas. Taken together, these studies highlight the importance of the ESCRT family gene VPS37D in breast cancer initiation, progression, and immune response.  \nConclusion: This study highlights ESCRT ’s potential in tumor detection via pan-cancer analysis, showing expression variations between tumor and normal tissues, its role in cancer progression through the immune microenvironment,  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nand its speciﬁcity and sensitivity in detection. The VPS37D gene, with signiﬁcant variation in breast cancer, pr","cbCainciXbsXiPI1","https://ap.wps.com/l/cbCainciXbsXiPI1","pdf",19030747,14,"English","# Background\n# Methods\n# Results\n# Conclusion\n# Introduction\n# Keywords","[{\"question\":\"What datasets and analytical tools were used to study ESCRT’s biomarker potential?\",\"answer\":\"The study used TCGA, GTEX, HPA, GEO, CPTAC, R software, and bioinformatics methods to mine expression, prognostic value, and immune relevance across tumor types.\"},{\"question\":\"What key findings support ESCRT as a tumor biomarker across cancers?\",\"answer\":\"ESCRT showed significant differential expression and abnormal expression was associated with poor prognosis in multiple cancers, alongside associations with immune infiltration and stromal/immune score modulation.\"},{\"question\":\"How is ESCRT further validated specifically for breast cancer?\",\"answer\":\"The workflow includes additional verification in breast cancer to confirm ESCRT family gene function and to highlight VPS37D’s role in tumor initiation, progression, and immune response.\"}]","ESCRT may function as a tumor biomarker - transitioning from pan-cancer analysis to validation within breast cancer | PDF",1790170494,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e60948553ef1161f360570dfd552f397.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99b6fbedfe9c3270e07fa96fee2b5655.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d3c24e01240ca7d13ff518b9d3e6bb99.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/016863603ab9ff99c482012507230f8f.webp",980,1385]